Holen Sie sich die Stockscreener-App
34.11
3.31%
-1.23
Schlusskurs vom Vortag:
$35.34
Offen:
$34.99
24-Stunden-Volumen:
668.16K
Relative Volume:
0.57
Marktkapitalisierung:
$2.99B
Einnahmen:
$23.38M
Nettoeinkommen (Verlust:
$-155.22M
KGV:
-15.58
EPS:
-2.19
Netto-Cashflow:
$-134.36M
1W Leistung:
+1.42%
1M Leistung:
+13.00%
6M Leistung:
+57.39%
1J Leistung:
+23.22%
1-Tages-Spanne:
$34.09
$35.57
1-Wochen-Bereich:
$33.14
$37.08
52-Wochen-Spanne:
$13.45
$37.08
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie IDYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
34.14 | 3.10B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.92 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.15 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.13 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.47 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-09-04 | Eingeleitet | Barclays | Overweight |
| 2025-09-04 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Eingeleitet | TD Cowen | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-26 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
GSK (GSK) Plans to End Agreement with Ideaya Biosciences - GuruFocus
Can IDEAYA Biosciences Stock Hold Up When Markets Turn? - Trefis
Why IDEAYA Biosciences Shares Are Under Pressure - TipRanks
GlaxoSmithKline to end collaboration with Ideaya Biosciences on two clinical programs - Investing.com Nigeria
IDEAYA Biosciences Shares Climb After FDA Clears Bispecific ADC Candidate - MSN
GSK ends collaboration with IDEAYA for two candidates - Seeking Alpha
IDEAYA Biosciences Receives Termination Notice from GSK - TradingView
Ideaya Biosciences stock hits 52-week high at 36.57 USD By Investing.com - Investing.com Nigeria
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance - Business Wire India
Will IDEAYA Biosciences Inc. (30J) stock profit from automation wave2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
IDE034, a Bispecific ADC Licensed by Biocytogen Pharmaceuticals Co., Ltd to IDEAYA Biosciences, Inc, Receives FDA IND Clearance - marketscreener.com
IDEAYA Biosciences (Nasdaq: IDYA) gets FDA IND for IDE034 Phase 1 solid tumor study - Stock Titan
How big funds are accumulating IDEAYA Biosciences Inc. (30J) stockJuly 2025 Fed Impact & AI Driven Price Forecasts - Newser
Ideaya Biosciences stock hits 52-week high at 36.57 USD - Investing.com
Is IDEAYA Biosciences Inc. (30J) stock a fit for income portfoliosGDP Growth & Weekly Top Gainers Trade List - Newser
Is IDEAYA Biosciences Inc. (30J) stock safe for risk averse investors2025 Performance Recap & AI Powered Buy and Sell Recommendations - Newser
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week HighTime to Buy? - MarketBeat
Transcript : IDEAYA Biosciences, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 09 - marketscreener.com
Can IDEAYA Biosciences Inc. stock beat market expectations this quarter2025 Top Gainers & High Yield Stock Recommendations - Newser
Can IDEAYA Biosciences Inc. stock beat analyst upgradesWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
Will IDEAYA Biosciences Inc. (30J) stock hit analyst forecastsTrade Ideas & Daily Profit Maximizing Tips - Newser
IDEAYA receives FDA approval to begin IDE034 clinical trial - Yahoo
Is IDEAYA Biosciences Inc. (30J) stock good for wealth creation2025 Big Picture & Technical Buy Zone Confirmation - Newser
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Citi Global Healthcare Conference - marketscreener.com
Ideaya Biosciences, Inc. Announces Ind Clearance for Ide034, A Potential First-In-Class Bispecific B7h3/Ptk7 Top1 Adc Targeting Multiple Solid Tumor Types - marketscreener.com
IDEAYA receives FDA clearance for bispecific cancer drug IDE034 By Investing.com - Investing.com Nigeria
Sector Update: Health Care Stocks Decline Pre-Bell Monday - marketscreener.com
IDEAYA Biosciences stock rises after FDA clearance for bispecific ADC By Investing.com - Investing.com Nigeria
IDEAYA Biosciences stock rises after FDA clearance for bispecific ADC - Investing.com
Ideaya’s IDE-034 gains IND clearance for solid tumors - BioWorld MedTech
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potenti - GuruFocus
IDEAYA Biosciences Gets FDA Clearance to Begin Phase 1 Trial of IDE034 in Early 2026 - marketscreener.com
Ideaya Biosciences announces clearance for IDE034 - marketscreener.com
Ideaya Biosciences Announces Clearance For IDE034 - TradingView
IDEAYA receives FDA clearance for bispecific cancer drug IDE034 - Investing.com
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types - WV News
Handelsbanken Fonder AB Has $561,000 Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
A Closer Look at IDEAYA Biosciences (IDYA) Valuation as Investor Optimism Builds - Yahoo Finance
IDEAYA Biosciences (IDYA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
SG Americas Securities LLC Makes New $423,000 Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
(IDYA) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
Ideaya Biosciences announces inducement grants under Nasdaq listing rule - TipRanks
Intech Investment Management LLC Sells 20,390 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences (NASDAQ: IDYA) issues 17,600 inducement stock options at $35.88 - Stock Titan
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events - Sahm
Geode Capital Management LLC Grows Stock Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
How sustainable is IDEAYA Biosciences Inc. stock dividend payoutJuly 2025 Decliners & Real-Time Volume Analysis Alerts - BỘ NỘI VỤ
Ideaya Biosciences stock reaches 52-week high of 35.13 USD By Investing.com - Investing.com Australia
Ideaya Biosciences: Primed For SuccessMajor Eye Cancer Catalyst Weeks Away (IDYA) - Seeking Alpha
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):